MELAS with multiple stroke-like episodes due to the variant m.13513G>A in MT-ND5

Ritwik Ghosh1, Souvik Dubey2, Subhas Bhuin2

  • 1Department of General Medicine Burdwan Medical College & Hospital Burdwan West Bengal India.

Clinical Case Reports
|February 10, 2022
PubMed

Insights

Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) can be caused by rare MT-ND5 gene variants. This case highlights a patient with a novel MT-ND5 variant presenting as MELAS, benefiting from antioxidant therapy.

Area of Science:

  • Genetics
  • Neurology
  • Mitochondrial Diseases

Background:

  • Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is a common mitochondrial disorder, typically caused by the m.3243A>G mtDNA variant.
  • The clinical presentation of MELAS includes stroke-like episodes, seizures, cognitive decline, and lactic acidosis.

Observation:

  • A 33-year-old male presented with recurrent stroke-like episodes (StLEs) and progressive cognitive decline over 10 years, initially misdiagnosed as ischemic strokes or cerebral vasculitis.
  • Cerebral imaging revealed characteristic stroke-like lesions in MELAS.
  • Genetic analysis identified a rare variant, m.13513G>A, in the MT-ND5 gene, encoding subunit 5 of Complex I in the mitochondrial respiratory chain.

Findings:

  • The identified MT-ND5 variant, m.13513G>A, is a rare cause of MELAS.
  • The patient showed significant clinical improvement with a treatment cocktail of antioxidants and cofactors.
  • This case demonstrates that StLEs in MELAS can resolve spontaneously and the disease course can be slowly progressive.

Implications:

  • This case expands the spectrum of genetic causes for MELAS, emphasizing the importance of considering rare MT-ND5 variants.
  • The positive response to antioxidant/cofactor therapy suggests a potential therapeutic strategy for patients with this specific MELAS-associated variant.
  • Early and accurate genetic diagnosis is crucial for appropriate management and understanding the long-term prognosis of MELAS.